ClinicalTrials.gg
RecruitingNCT03858231Updated Feb 10, 2026

Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery

A Phase 4 interventional study of Norco 5Mg-325Mg Tablet and Ibuprofen 600 mg in Knee Injuries, Pain, Postoperative and Opioid Use, sponsored by Sanford Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Sanford Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2018, registered Feb 2019).
  • Started Oct 2018; still recruiting 8 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Knee Injuries with a site in United States — 16 open to participants now, 24 under way, 1 of them phase 3. Knee Injuries · United States.

Planned enrollment
8th of 75
148 · median 40
Started
2018
with 7 others
Phase 4
2 of 94
1 open now
Primary completion
2027-12
later than 17 of 23 live
Registered
45th of 94
by date

Among the 94 studies in Knee Injuries with a site in United States, this one is the 8th largest by planned enrollment of the 75 interventional ones that give a count, is one of 8 that started in 2018, is one of 2 in phase 4, reaches primary completion later than 17 of the 23 other live ones, and was the 45th registered.

Knee Injuries

267 studies on the registry are indexed under Knee Injuries; 59 are open to participants now.

Browse Knee Injuries studies →

Open to participants now

16 of the 94 studies in Knee Injuries with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Knee Injuries studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Knee Injuries with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to look at pain management with opioids versus non-opioids after knee arthroscopy. This study will determine 1) whether the most commonly used non-narcotic medications provide pain relief comparable with the most commonly prescribed narcotic medications in patients undergoing arthroscopic knee surgery, and 2) whether patients' characteristics (gender, pre-operative knee symptoms, workers compensation status and employment status) affect pain level following surgery or medication usage.

03

Conditions studied

  • Knee Injuries
  • Pain, Postoperative
  • Opioid Use
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects ≥ 18 years of age through ≤ 80 years of age
  2. Subjects undergoing elective arthroscopic knee surgery, to include partial meniscectomy, chondroplasty, or loose body removal.

Exclusion criteria

Exclusion Criteria:

  1. Previously enrolled in this study (enrolled for contralateral knee in this study)
  2. Knee arthroscopy patients scheduled for knee ligament reconstructions
  3. Bilateral knee arthroscopy
  4. History of chronic opioid use or long-term analgesic therapy
  5. Documented or suspected substance abuse
  6. Documented or suspected chronic pain syndrome
  7. Any known allergy or adverse reaction or to the components of hydrocodone, acetaminophen, or ibuprofen
  8. History or symptoms of any significant medical problem in the last year (i.e., arrhythmia, impaired cardiovascular function, gastrointestinal bleeding, liver disease, renal disease)
  9. With active peptic ulcer disease (history of severe heartburn)
  10. Symptoms of infection with initial enrollment
  11. Pregnant or nursing
  12. Diagnosis of cognitive impairment
  13. Unable or unwilling to provide for surgery or enrollment in this clinical study
  14. Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by Institutional Review Board) and agree to abide by the study restrictions.
  15. Patient refusal
  16. Currently taking Coumadin, Plavix, anticoagulation medications, or medications that increase bleeding, with the exception of ASA 81mg.
  17. Patients with other medical or psychological health conditions that preclude them from either receiving the intervention or returning for follow-up visits.
  18. Alcoholism
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
148 participants (estimated)

Study arms

  • Active comparator
    Opioid

    Drug: Norco 5Mg-325Mg Tablet

  • Active comparator
    Non-opioid

    Drug: Ibuprofen 600 mg · Drug: Acetaminophen 325Mg Tab

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline Pain Assessment at 2 weeks

    Visual Analog Scale from 0 to 10 with 0 being no pain and 10 being worst possible, unbearable, excruciating pain

    Time frame: Daily for 2 weeks post-operatively

  2. Change from Baseline Medication Use at 2 weeks

    Patients will be asked how many study medication capsules have they taken.

    Time frame: Daily for 14 days post-operatively

Secondary outcomes

  1. Change from Baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6 weeks

    Sub-scales are listed as follows: 5 qualitative questions related to knee symptoms ranging from "never" to "always", 2 qualitative questions related to knee stiffness ranging from "none" to "extreme", 9 qualitative questions related to pain ranging from "none" to "extreme", 17 qualitative questions related to function and daily living ranging from "none" to "extreme", 5 qualitative questions related to function and sports and recreational activities ranging from "none" to "extreme", and 4 qualitative questions related to quality of life ranging from "never or not at all" to "constantly, totally, or extreme".

    Time frame: baseline, 2 weeks, and 6 weeks post-operatively

  2. Change from Baseline Patient Reported Outcome Measurement Information System (PROMIS) at 6 weeks

    7 qualitative questions related to pain interference with responses ranging from "not at all" to "very much"

    Time frame: baseline, 2 weeks, and 6 weeks post-operatively

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2018 (actual). Primary completion is estimated for Dec 2027, 110 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Feb 28, 2019
StartActual
Oct 29, 2018
Primary completionEst.
Dec 2027
CompletionEst.
Jan 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03858231
Lead sponsor
Sanford Health
Responsible party
Sponsor
First posted
Feb 28, 2019
Start date
Oct 29, 2018
Primary completion
Dec 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Amy Tuchscherer
Contact
amy.tuchscherer@sanfordhealth.org
(701) 417-6292
Katie Jensen
Contact
Katie.E.Jensen@SanfordHealth.org
(605) 312-6983
Bruce Piatt, MD
principal investigator · Sanford Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydrocodone · Acetaminophen · Ibuprofen

Start the discussion